OPKO Health sets $640M-$660M revenue target for 2025, driven by BioReference sale and pipeline advancements.

OPKO Health is targeting $640M-$660M in revenue for 2025, driven by the sale of its BioReference Health oncology and clinical testing business to Labcorp and advancements in its pipeline. The company is pushing towards profitability through these strategic initiatives.

OPKO Health, Inc. (OPK) reported mixed results for the second quarter of 2025, with revenue declining year-over-year but significant advancements in its pipeline and strategic initiatives aimed at profitability. The company reported $156.8 million in revenue for the quarter, a 13.9% year-over-year decline compared to $182.2 million in Q2 2024 [1][2]. The earnings per share (EPS) for the quarter were -$0.19, compared to -$0.01 a year ago, representing a significant surprise of -58.33% over the consensus estimate of -$0.12 [1][2].

Key revenue metrics showed varied performance. Revenue from the transfer of intellectual property and other sources increased by 22% to $15 million, while revenue from products remained relatively stable at $40.7 million, up by 0.5% compared to the same period last year. However, revenue from services decreased by 21.9% to $101.1 million [1][2].

OPKO Health is targeting $640 million to $660 million in revenue for 2025, driven by the sale of its BioReference Health oncology and clinical testing business to LabCorp and advancements in its pipeline [3]. The company is aiming to achieve profitability through these strategic initiatives, which include the development of new therapies and the optimization of existing ones.

Shares of OPKO Health have remained unchanged over the past month, while the Zacks S&P 500 composite has increased by 2.7%. The stock currently holds a Zacks Rank #4 (Sell), indicating potential underperformance in the near term [1][2].

References:
[1] https://finance.yahoo.com/news/compared-estimates-opko-health-opk-230002593.html
[2] https://www.nasdaq.com/articles/compared-estimates-opko-health-opk-q2-earnings-look-key-metrics
[3] https://finance.yahoo.com/news/opko-health-reports-second-quarter-200500684.html